ICCM vs. NVRO, DRTS, SKIN, CATX, BWAY, LAKE, ELMD, CVRX, RCEL, and SGHT
Should you be buying IceCure Medical stock or one of its competitors? The main competitors of IceCure Medical include Nevro (NVRO), Alpha Tau Medical (DRTS), Beauty Health (SKIN), Perspective Therapeutics (CATX), BrainsWay (BWAY), Lakeland Industries (LAKE), Electromed (ELMD), CVRx (CVRX), AVITA Medical (RCEL), and Sight Sciences (SGHT). These companies are all part of the "medical equipment" industry.
IceCure Medical vs.
IceCure Medical (NASDAQ:ICCM) and Nevro (NYSE:NVRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership, risk and community ranking.
Nevro received 478 more outperform votes than IceCure Medical when rated by MarketBeat users. However, 96.30% of users gave IceCure Medical an outperform vote while only 62.07% of users gave Nevro an outperform vote.
0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 95.5% of Nevro shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 3.2% of Nevro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
IceCure Medical presently has a consensus target price of $2.50, indicating a potential upside of 145.10%. Nevro has a consensus target price of $5.36, indicating a potential downside of 8.29%. Given IceCure Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe IceCure Medical is more favorable than Nevro.
IceCure Medical has higher earnings, but lower revenue than Nevro. IceCure Medical is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.
IceCure Medical has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Nevro has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
Nevro has a net margin of -16.54% compared to IceCure Medical's net margin of -376.85%. Nevro's return on equity of -23.52% beat IceCure Medical's return on equity.
In the previous week, IceCure Medical had 2 more articles in the media than Nevro. MarketBeat recorded 3 mentions for IceCure Medical and 1 mentions for Nevro. IceCure Medical's average media sentiment score of 0.42 beat Nevro's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media.
Summary
IceCure Medical and Nevro tied by winning 9 of the 18 factors compared between the two stocks.
Get IceCure Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IceCure Medical Competitors List
Related Companies and Tools
This page (NASDAQ:ICCM) was last updated on 5/22/2025 by MarketBeat.com Staff
